Monte Rosa Therapeutics (GLUE) Cash & Current Investments: 2023-2025
Historic Cash & Current Investments for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $401.6 million.
- Monte Rosa Therapeutics' Cash & Current Investments rose 219.83% to $401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 148.61%. This contributed to the annual value of $381.0 million for FY2024, which is 61.14% up from last year.
- Monte Rosa Therapeutics' Cash & Current Investments amounted to $401.6 million in Q3 2025, which was up 33.49% from $300.9 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Cash & Current Investments' 5-year high stood at $401.6 million during Q3 2025, with a 5-year trough of $47.0 million in Q2 2023.
- In the last 3 years, Monte Rosa Therapeutics' Cash & Current Investments had a median value of $125.6 million in 2024 and averaged $195.3 million.
- Data for Monte Rosa Therapeutics' Cash & Current Investments shows a peak YoY skyrocketed of 235.91% (in 2025) over the last 5 years.
- Monte Rosa Therapeutics' Cash & Current Investments (Quarterly) stood at $236.4 million in 2023, then soared by 61.14% to $381.0 million in 2024, then skyrocketed by 219.83% to $401.6 million in 2025.
- Its last three reported values are $401.6 million in Q3 2025, $300.9 million for Q2 2025, and $335.1 million during Q1 2025.